Last reviewed · How we verify
Voglibose (Basen)
Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels.
Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Voglibose (Basen) |
|---|---|
| Sponsor | Bayer |
| Drug class | Alpha-glucosidase inhibitor |
| Target | Alpha-glucosidase enzymes |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting enzymes (alpha-glucosidase) that break down disaccharides and complex carbohydrates, voglibose delays glucose absorption and flattens the postprandial glucose curve. This reduces peak blood glucose excursions after meals in patients with type 2 diabetes without stimulating insulin secretion directly.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)
- Abdominal pain
- Diarrhea
Key clinical trials
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
- Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes (PHASE4)
- Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes (PHASE4)
- Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT (NA)
- MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |